Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gout relief: should you take meds immediately?

NCT ID NCT05109936

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving gout medication (febuxostat) right after an attack is better than waiting 6 weeks, which is the current standard. About 128 people with gout will be split into two groups to compare how many days they have gout symptoms. The goal is to see if early treatment can reduce pain and prevent the disease from getting worse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 128 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2023

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with an attack of gout, diagnosed immediately or less than 5 days old. Gout is defined according to American-European criteria (Appendix 3). 2. Attack of gout affecting one (or more) peripheral joint (s) whatever (s) it (s): * Either a first crisis, * Either a new attack of a gout not treated with a hypo-uricemic or for which the hypo-uricemic treatment has not been taken for at least 6 months. 3. Uricemia ≥ 420 µmol / l, including under a diuretic (dosage carried out within 10 days before inclusion), 4. Age ≥ 18 years old, 5. Patient with a creatinine clearance ≥ 30 ml / min (dosage carried out within 10 days before inclusion), 6. Patient having read and understood the information letter and signed the consent form, 7. Affiliation to a social security scheme, 8. Woman of childbearing potential with effective contraception according to WHO definition (estrogen-progestins or intrauterine device or tubal ligation for more than 1 month and to be continued for at least 5 weeks after the last dose of the drug. ) and a negative urine pregnancy test on inclusion and throughout the duration of the study Where Postmenopausal woman: amenorrhea not medically induced for at least 12 months before the inclusion visit. Exclusion Criteria: 1. Patients under the age of 18, 2. Stop taking a hypouricemic agent for less than 6 months, 3. Known contraindication to ADENURIC 80 mg film-coated tablet: hypersensitivity to the active substance (febuxostat) or to one of the excipients, 4. Renal failure defined by creatinine clearance \<30 ml / min, 5. Hepatic disease defined by an increase to more than 2 times the normal of transaminases, alkaline phosphatases, to more than 3 times the normal of gamma-GT, 6. Non-weaned alcoholism, 7. Crisis more than 5 days old, 8. Patient who has received an organ or marrow transplant, 9. Person on Naproxen, mercaptopurine, azathioprine, Glycuronidation inhibitors and inducers, theophylline, macrolides, HMG Co-A reductase inhibitors and / or diuretic in combination with an ACE inhibitor or ARAII, 10. Person with rare hereditary disorders of galactose intolerance, lactase deficiency or glucose / galactose malabsorption 11. Poor understanding of the project due to neurological disease or lack of French practice, 12. Pregnant woman or likely to be in the absence of effective contraception (Women of childbearing age should have a negative urine pregnancy test), 13. Breastfeeding woman 14. Any history of pre-existing major cardiovascular disease (myocardial infarction, stroke, unstable angina, etc.), metabolic, endocrine, psychiatric or cancerous in uncontrolled development, 15. Person deprived of liberty by an administrative or judicial decision, 16. Person placed under judicial protection, guardianship or curatorship, 17. Participating patient who participated in the month preceding inclusion in another interventional drug trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gout are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHG Dieppe

    RECRUITING

    Dieppe, France

  • CHI Elbeuf, Louvier, Val de Reuil

    RECRUITING

    Elbeuf, France

  • CHU de Caen

    RECRUITING

    Caen, France

  • CHU de Rouen

    RECRUITING

    Rouen, France

  • Centre Hospitalier Public du Cotentin

    RECRUITING

    Cherbourg, France

  • GH Le Havre

    RECRUITING

    Le Havre, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.